Literature DB >> 24294903

A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids.

P Mangeney, R Z Andriamialisoa, N Langlois, Y Langlois, P Potier.   

Abstract

Entities:  

Year:  1979        PMID： 24294903     DOI： 10.1021/jo01336a006

Source DB:  PubMed          Journal:  J Org Chem        ISSN： 0022-3263            Impact factor:   4.354


× No keyword cloud information.
  12 in total

Review 1.  A review of the antitumour activity of vinorelbine in breast cancer.

Authors:  M Marty; J M Extra; V Dieras; S Giacchetti; S Ohana; M Espié
Journal:  Drugs       Date:  1992       Impact factor: 9.546

2.  High expression of class III β-tubulin has no impact on functional cancer cell growth inhibition of a series of key vinblastine analogs.

Authors:  Aleksandar Radakovic; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2018-02-06       Impact factor: 2.823

3.  A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.

Authors:  Shih-Hung Yang; Chia-Chi Lin; Zhong-Zhe Lin; Yun-Long Tseng; Ruey-Long Hong
Journal:  Invest New Drugs       Date:  2010-09-01       Impact factor: 3.850

Review 4.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 5.  The current and future place of vinorelbine in cancer therapy.

Authors:  E Cvitkovic; J Izzo
Journal:  Drugs       Date:  1992       Impact factor: 9.546

6.  Biliary elimination and pharmacokinetics of vinorelbine in micropigs.

Authors:  D Levêque; M Merle-Melet; L Bresler; J P Didelot; J P Aymard; J Wihlm; F Jehl
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Experimental in vivo cross-resistance of vinca alkaloid drugs.

Authors:  R Maral; C Bourut; E Chenu; G Mathe
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.

Authors:  Thomas E Hutson; Ram Ganapathi; Paul Elson; Tarek Mekhail; Thomas Olencki; G Thomas Budd; Ronald M Bukowski
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

9.  Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.

Authors:  R Rahmani; F Guéritte; M Martin; S Just; J P Cano; J Barbet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Pharmacokinetics of navelbine after oral administration in cancer patients.

Authors:  X J Zhou; P Boré; S Monjanel; Z Sahnoun; R Favre; A Durand; R Rahmani
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.